Cargando…

Survival outcomes of lung metastases from colorectal cancer treated with pulmonary metastasectomy or modern systemic chemotherapy: a single institution experience

BACKGROUND: Although pulmonary metastasectomy is an accepted treatment strategy for resectable lung metastases (LM) from colorectal cancer (CRC), its survival benefits are controversial. In contrast, recent advancements in chemotherapy have significantly improved metastatic CRC prognosis. This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Shishido, Yutaka, Ishii, Masayuki, Maeda, Tetsuo, Kokado, Yujiro, Masuya, Daiki, Kusama, Toshiyuki, Fujimoto, Koji, Higashiyama, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647062/
https://www.ncbi.nlm.nih.gov/pubmed/37964370
http://dx.doi.org/10.1186/s13019-023-02434-8
_version_ 1785147492081336320
author Shishido, Yutaka
Ishii, Masayuki
Maeda, Tetsuo
Kokado, Yujiro
Masuya, Daiki
Kusama, Toshiyuki
Fujimoto, Koji
Higashiyama, Hiroshi
author_facet Shishido, Yutaka
Ishii, Masayuki
Maeda, Tetsuo
Kokado, Yujiro
Masuya, Daiki
Kusama, Toshiyuki
Fujimoto, Koji
Higashiyama, Hiroshi
author_sort Shishido, Yutaka
collection PubMed
description BACKGROUND: Although pulmonary metastasectomy is an accepted treatment strategy for resectable lung metastases (LM) from colorectal cancer (CRC), its survival benefits are controversial. In contrast, recent advancements in chemotherapy have significantly improved metastatic CRC prognosis. This study aimed to evaluate survival outcome of LM from CRC in the age of newly developed chemotherapy. METHODS: We retrospectively reviewed 50 patients who underwent complete resection and 22 patients who received chemotherapy as definitive treatment for LM from resected CRC at our hospital. The present study was limited to patients who started treatment for isolated LM after molecular targeted drugs became available in Japan. RESULTS: Overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS) rates after pulmonary resection were 64.5%, 66.4%, and 32.6% at five years, respectively. OS and CSS rates of chemotherapy patients were 26.8% and 28.3% at five years, with a median progression-free survival time of 10.0 months. When compared the characteristics of surgical and chemotherapy patients, patients with pN factors of CRC (p = 0.013), smaller size (p < 0.001), larger number (p < 0.001), and bilateral (p < 0.001) LM received chemotherapy. Univariate analysis showed that multiple LM and rectal lesions were poor prognostic factors for OS (p = 0.012) and DFS (p = 0.017) in surgical patients, and rectal lesions were a poor prognostic factor for OS (p = 0.013) in chemotherapy patients. CONCLUSIONS: Pulmonary metastasectomy showed a favorable survival in patients with LM from CRC. Despite the high recurrence rate after metastasectomy and recent advances in chemotherapy, surgical resection could still be considered as a valid option among multidisciplinary treatments. TRIAL REGISTRATION: The research plan was approved by the Institutional Review Board of Shinko Hospital (No. 2142) on February 7, 2022.
format Online
Article
Text
id pubmed-10647062
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106470622023-11-14 Survival outcomes of lung metastases from colorectal cancer treated with pulmonary metastasectomy or modern systemic chemotherapy: a single institution experience Shishido, Yutaka Ishii, Masayuki Maeda, Tetsuo Kokado, Yujiro Masuya, Daiki Kusama, Toshiyuki Fujimoto, Koji Higashiyama, Hiroshi J Cardiothorac Surg Research BACKGROUND: Although pulmonary metastasectomy is an accepted treatment strategy for resectable lung metastases (LM) from colorectal cancer (CRC), its survival benefits are controversial. In contrast, recent advancements in chemotherapy have significantly improved metastatic CRC prognosis. This study aimed to evaluate survival outcome of LM from CRC in the age of newly developed chemotherapy. METHODS: We retrospectively reviewed 50 patients who underwent complete resection and 22 patients who received chemotherapy as definitive treatment for LM from resected CRC at our hospital. The present study was limited to patients who started treatment for isolated LM after molecular targeted drugs became available in Japan. RESULTS: Overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS) rates after pulmonary resection were 64.5%, 66.4%, and 32.6% at five years, respectively. OS and CSS rates of chemotherapy patients were 26.8% and 28.3% at five years, with a median progression-free survival time of 10.0 months. When compared the characteristics of surgical and chemotherapy patients, patients with pN factors of CRC (p = 0.013), smaller size (p < 0.001), larger number (p < 0.001), and bilateral (p < 0.001) LM received chemotherapy. Univariate analysis showed that multiple LM and rectal lesions were poor prognostic factors for OS (p = 0.012) and DFS (p = 0.017) in surgical patients, and rectal lesions were a poor prognostic factor for OS (p = 0.013) in chemotherapy patients. CONCLUSIONS: Pulmonary metastasectomy showed a favorable survival in patients with LM from CRC. Despite the high recurrence rate after metastasectomy and recent advances in chemotherapy, surgical resection could still be considered as a valid option among multidisciplinary treatments. TRIAL REGISTRATION: The research plan was approved by the Institutional Review Board of Shinko Hospital (No. 2142) on February 7, 2022. BioMed Central 2023-11-14 /pmc/articles/PMC10647062/ /pubmed/37964370 http://dx.doi.org/10.1186/s13019-023-02434-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Shishido, Yutaka
Ishii, Masayuki
Maeda, Tetsuo
Kokado, Yujiro
Masuya, Daiki
Kusama, Toshiyuki
Fujimoto, Koji
Higashiyama, Hiroshi
Survival outcomes of lung metastases from colorectal cancer treated with pulmonary metastasectomy or modern systemic chemotherapy: a single institution experience
title Survival outcomes of lung metastases from colorectal cancer treated with pulmonary metastasectomy or modern systemic chemotherapy: a single institution experience
title_full Survival outcomes of lung metastases from colorectal cancer treated with pulmonary metastasectomy or modern systemic chemotherapy: a single institution experience
title_fullStr Survival outcomes of lung metastases from colorectal cancer treated with pulmonary metastasectomy or modern systemic chemotherapy: a single institution experience
title_full_unstemmed Survival outcomes of lung metastases from colorectal cancer treated with pulmonary metastasectomy or modern systemic chemotherapy: a single institution experience
title_short Survival outcomes of lung metastases from colorectal cancer treated with pulmonary metastasectomy or modern systemic chemotherapy: a single institution experience
title_sort survival outcomes of lung metastases from colorectal cancer treated with pulmonary metastasectomy or modern systemic chemotherapy: a single institution experience
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647062/
https://www.ncbi.nlm.nih.gov/pubmed/37964370
http://dx.doi.org/10.1186/s13019-023-02434-8
work_keys_str_mv AT shishidoyutaka survivaloutcomesoflungmetastasesfromcolorectalcancertreatedwithpulmonarymetastasectomyormodernsystemicchemotherapyasingleinstitutionexperience
AT ishiimasayuki survivaloutcomesoflungmetastasesfromcolorectalcancertreatedwithpulmonarymetastasectomyormodernsystemicchemotherapyasingleinstitutionexperience
AT maedatetsuo survivaloutcomesoflungmetastasesfromcolorectalcancertreatedwithpulmonarymetastasectomyormodernsystemicchemotherapyasingleinstitutionexperience
AT kokadoyujiro survivaloutcomesoflungmetastasesfromcolorectalcancertreatedwithpulmonarymetastasectomyormodernsystemicchemotherapyasingleinstitutionexperience
AT masuyadaiki survivaloutcomesoflungmetastasesfromcolorectalcancertreatedwithpulmonarymetastasectomyormodernsystemicchemotherapyasingleinstitutionexperience
AT kusamatoshiyuki survivaloutcomesoflungmetastasesfromcolorectalcancertreatedwithpulmonarymetastasectomyormodernsystemicchemotherapyasingleinstitutionexperience
AT fujimotokoji survivaloutcomesoflungmetastasesfromcolorectalcancertreatedwithpulmonarymetastasectomyormodernsystemicchemotherapyasingleinstitutionexperience
AT higashiyamahiroshi survivaloutcomesoflungmetastasesfromcolorectalcancertreatedwithpulmonarymetastasectomyormodernsystemicchemotherapyasingleinstitutionexperience